Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus

Gene Therapy

Volumn 19, Issue 1, 2012, Pages 25-33

  Chen, C C ^a   Chang, C M ^a,b   Sun, C P ^a,c   Yu, C P ^d   Wu, P Y ^a   Jeng, K S ^e   Hu, C P ^f   Chen, P J ^g   Wu, J C ^c   Shih, C H ^a   Gershwin, M E ^h   Tao, M H ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^f TUNGHAI UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adeno associated virus; adenoma; hepatitis B virus; RNA interference

Indexed keywords

ADENOVIRUS VECTOR; LIVER ENZYME; LUCIFERASE; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER CELL DAMAGE; LIVER REGENERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; VIRUS GENOME; VIRUS REPLICATION;

ADENOMA, LIVER CELL; ANIMALS; BLOTTING, NORTHERN; DEPENDOVIRUS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENE TRANSFER TECHNIQUES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; LUCIFERASES; MALE; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA, VIRAL; TRANSGENES; VIRAL LOAD; VIRUS REPLICATION;

ADENO-ASSOCIATED VIRUS; ANIMALIA; HEPATITIS B VIRUS; MURINAE; MUS MUSCULUS;

EID: 84855419338     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.60     Document Type: Article

References (40)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129. (Pubitemid 38298992)
2. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211, v.
3. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
4. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686. (Pubitemid 43374518)
5. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751. (Pubitemid 44958517)
7. Mailliard ME, Gollan JL. Emerging therapeutics for chronic hepatitis B. Annu Rev Med 2006; 57: 155-166. (Pubitemid 43261984)
8. Konishi M, Wu CH, Wu GY. Inhibition of HBV replication by siRNA in a stable HBVproducing cell line. Hepatology 2003; 38: 842-850. (Pubitemid 37221667)
9. Wu HL, Huang LR, Huang CC, Lai HL, Liu CJ, Huang YT et al. RNA interferencemediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology 2005; 128: 708-716.
10. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21: 639-644. (Pubitemid 36638090)
11. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-1007. (Pubitemid 41114035)
12. Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci USA 2005; 102: 773-778. (Pubitemid 40282741)
13. Chen CC, Ko TM, Ma HI, Wu HL, Xiao X, Li J et al. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Therapy 2007; 14: 11-19. (Pubitemid 44942861)
14. Chen CC, Sun CP, Ma HI, Fang CC, Wu PY, Xiao X et al. Comparative study of antihepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. Mol Ther 2009; 17: 352-359.
15. Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. J Virol 1995; 69: 6158-6169.
16. Meuleman P, Libbrecht L, Wieland S, De Vos R, Habib N, Kramvis A et al. Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol 2006; 80: 2797-2807. (Pubitemid 43346374)
17. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341-350. (Pubitemid 28357762)
18. Shimizu Y, Guidotti LG, Fowler P, Chisari FV. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 1998; 161: 4520-4529. (Pubitemid 28492022)
19. Farza H, Hadchouel M, Scotto J, Tiollais P, Babinet C, Pourcel C. Replication and gene expression of hepatitis B virus in a transgenic mouse that contains the complete viral genome. J Virol 1988; 62: 4144-4152.
20. Araki K, Miyazaki J, Hino O, Tomita N, Chisaka O, Matsubara K et al. Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci USA 1989; 86: 207-211. (Pubitemid 19036356)
21. Araki K, Nishimura S, Ochiya T, Okubo K, Miyazaki J, Matsubara K et al. Production and effect of infectious Dane particles in transgenic mice. Jpn J Cancer Res 1991; 82: 235-239.
22. Zheng Y, Chen WL, Louie SG, Yen TS, Ou JH. Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice. Hepatology 2007; 45: 16-21. (Pubitemid 46144360)
23. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829. (Pubitemid 29291352)
24. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH et al. CD8(f) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76. (Pubitemid 36004947)
25. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
26. Sugiyama M, Tanaka Y, Kurbanov F, Maruyama I, Shimada T, Takahashi S et al. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. Gastroenterology 2009; 136: 652-662, e653.
27. Xu Z, Yen TS, Wu L, Madden CR, Tan W, Slagle BL et al. Enhancement of hepatitis B virus replication by its X protein in transgenic mice. J Virol 2002; 76: 2579-2584. (Pubitemid 34150729)
28. Koo JS, Seong JK, Park C, Yu DY, Oh BK, Oh SH et al. Large liver cell dysplasia in hepatitis B virus x transgenic mouse liver and human chronic hepatitis B virus-infected liver. Intervirology 2005; 48: 16-22. (Pubitemid 40529206)
29. Keng VW, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, Matise I et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 2009; 27: 264-274.
30. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007; 11: 797-816, viii. (Pubitemid 350019025)
31. DeLoia JA, Burk RD, Gearhart JD. Developmental regulation of hepatitis B surface antigen expression in two lines of hepatitis B virus transgenic mice. J Virol 1989; 63: 4069-4073. (Pubitemid 19205488)
32. Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS, Chen PJ. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology 2009; 50: 1392-1402.
33. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52.
34. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007; 12: 1295-1303.
35. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145-1156. (Pubitemid 20024625)
36. Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 1990; 50: 3400-3407. (Pubitemid 20190150)
37. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-320. (Pubitemid 21896589)
38. Yu DY, Moon HB, Son JK, Jeong S, Yu SL, Yoon H et al. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol 1999; 31: 123-132. (Pubitemid 29287618)
39. Lee TH, Finegold MJ, Shen RF, DeMayo JL, Woo SL, Butel JS. Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice. J Virol 1990; 64: 5939-5947.
40. Chou YC, Jeng KS, Chen ML, Liu HH, Liu TL, Chen YL et al. Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method. J Virol 2005; 79: 1813-1823.